Drugs / IONIS-AGT-LRx
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03101878 | Apr 2017 → Mar 2018 | — | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04836182 | Jun 2021 → Oct 2022 | symptomatic heart failure | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04714320 | Apr 2021 → Jun 2022 | hypertensive disorder | Ionis Pharmaceuticals, Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IONIS-AGT-L(Rx) | “Antisense Inhibition of Angiotensinogen With IONIS-AGT-L(Rx): Results of Phase 1 and Phase 2 Studies.” PMID 34222719 ↗ May 2021 |
| Action | Inhibit | “IONIS-AGT-LRx significantly reduced AGT levels compared with placebo in all 3 studies.” PMID 34222719 ↗ May 2021 |
| Modality | Antisense oligonucleotide | “Antisense Inhibition of Angiotensinogen With IONIS-AGT-L(Rx)” PMID 34222719 ↗ May 2021 |
| Route | Subcutaneous | “Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously.” NCT03101878 ↗ |